230 related articles for article (PubMed ID: 35218276)
1. Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study.
Piros ÉA; Cseprekál O; Görög A; Hidvégi B; Medvecz M; Szabó Z; Olajos F; Barabás E; Galajda N; Miheller P; Holló P
Dermatol Ther; 2022 May; 35(5):e15408. PubMed ID: 35218276
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
3. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
4. Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
Giannoccaro MP; Vacchiano V; Leone M; Camilli F; Zenesini C; Panzera I; Balboni A; Tappatà M; Borghi A; Salvi F; Lugaresi A; Rinaldi R; Di Felice G; Lodi V; Lazzarotto T; Liguori R;
J Neurol; 2022 Aug; 269(8):4000-4012. PubMed ID: 35503375
[TBL] [Abstract][Full Text] [Related]
5. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
6. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
Front Immunol; 2021; 12():780594. PubMed ID: 34925359
[TBL] [Abstract][Full Text] [Related]
7. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis.
Ionita C; Marcelli D; Nita C; Anton C; Berca S; Vacar S; Schiller O; Gheorghiu C; Barth C
J Nephrol; 2022 Jan; 35(1):143-151. PubMed ID: 34978050
[TBL] [Abstract][Full Text] [Related]
9. The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.
Al-Janabi A; Ra A; Littlewood Z; Foulkes AC; Hunter HJA; Chinoy H; Moriarty CA; Hyrich KL; Limdi JK; Yiu ZZN; Griffiths CEM; Warren RB
Br J Dermatol; 2023 Mar; 188(4):542-551. PubMed ID: 36695406
[TBL] [Abstract][Full Text] [Related]
10. Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors.
Pietroluongo E; De Placido P; Tortora M; Martinelli C; Viggiano A; Saponaro MR; Caltavituro A; Buonaiuto R; Morra R; Ottaviano M; Del Deo V; Cernera G; Gelzo M; Malfitano AM; Di Tolla MF; De Angelis C; Arpino G; Terracciano D; Bianco R; Veneziani BM; Formisano P; Castaldo G; Palmieri G; De Placido S; Giuliano M
J Thorac Oncol; 2023 Oct; 18(10):1399-1407. PubMed ID: 37390981
[TBL] [Abstract][Full Text] [Related]
11. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
12. Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria.
Kamura Y; Sakamoto T; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Chiba S; Obara N
Int J Hematol; 2022 Jul; 116(1):55-59. PubMed ID: 35668275
[TBL] [Abstract][Full Text] [Related]
13. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.
Amatu A; Pani A; Patelli G; Gagliardi OM; Loparco M; Piscazzi D; Cassingena A; Tosi F; Ghezzi S; Campisi D; Grifantini R; Abrignani S; Siena S; Scaglione F; Sartore-Bianchi A
Eur J Cancer; 2022 Mar; 163():16-25. PubMed ID: 35032813
[TBL] [Abstract][Full Text] [Related]
14. Association of Systemic Adverse Reactions and Serum SARS-CoV-2 Spike Protein Antibody Levels after Administration of BNT162b2 mRNA COVID-19 Vaccine.
Takahashi W; Mizuno T; Hara K; Ara Y; Hurutani R; Agatsuma T; Fujimori M
Intern Med; 2022 Nov; 61(21):3205-3210. PubMed ID: 35989281
[TBL] [Abstract][Full Text] [Related]
15. Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact Study.
Bareiß A; Uzun G; Mikus M; Becker M; Althaus K; Schneiderhan-Marra N; Fürstberger A; Schwab JD; Kestler HA; Holderried M; Martus P; Schenke-Layland K; Bakchoul T
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680106
[TBL] [Abstract][Full Text] [Related]
16. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients.
Saiag E; Grupper A; Avivi I; Elkayam O; Ram R; Herishanu Y; Cohen Y; Perry C; Furer V; Katchman H; Rabinowich L; Ben-Yehoyada M; Halperin T; Baruch R; Goldshmidt H; Hagin D; Ben-Ami R; Sprecher E; Bomze D
Clin Microbiol Infect; 2022 May; 28(5):735.e5-735.e8. PubMed ID: 35183747
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Gounant V; Ferré VM; Soussi G; Charpentier C; Flament H; Fidouh N; Collin G; Namour C; Assoun S; Bizot A; Brouk Z; Vicaut E; Teixeira L; Descamps D; Zalcman G
J Thorac Oncol; 2022 Feb; 17(2):239-251. PubMed ID: 34798306
[TBL] [Abstract][Full Text] [Related]
18. Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome.
Streng BMM; Bont M; Delemarre EM; Binnendijk RS; Smit G; den Hartog G; Coppus AMW; de Vries E; Weijerman ME; Lamberts R; de Graaf G; van der Klis FR; Vidarsson G; Rave N; Bont LJ; Wildenbeest JG
J Infect Dis; 2022 Sep; 226(4):673-677. PubMed ID: 35748853
[TBL] [Abstract][Full Text] [Related]
19. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
20. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]